You-Take Oh

844 total citations
23 papers, 672 citations indexed

About

You-Take Oh is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, You-Take Oh has authored 23 papers receiving a total of 672 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 11 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in You-Take Oh's work include Cell death mechanisms and regulation (14 papers), Cancer-related Molecular Pathways (6 papers) and Melanoma and MAPK Pathways (4 papers). You-Take Oh is often cited by papers focused on Cell death mechanisms and regulation (14 papers), Cancer-related Molecular Pathways (6 papers) and Melanoma and MAPK Pathways (4 papers). You-Take Oh collaborates with scholars based in United States, China and South Korea. You-Take Oh's co-authors include Shi‐Yong Sun, Ping Yue, Taofeek K. Owonikoko, Fadlo R. Khuri, Suresh S. Ramalingam, Guojing Zhang, Puyu Shi, Weilong Yao, Jiusheng Deng and Guoqing Qian and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and Oncogene.

In The Last Decade

You-Take Oh

23 papers receiving 664 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
You-Take Oh United States 14 506 251 232 94 82 23 672
Cristina Bugés Spain 9 387 0.8× 354 1.4× 113 0.5× 153 1.6× 87 1.1× 21 693
Virginie Poindessous France 17 484 1.0× 282 1.1× 123 0.5× 187 2.0× 61 0.7× 32 837
Swarupa G. Kulkarni United States 10 507 1.0× 293 1.2× 103 0.4× 85 0.9× 94 1.1× 17 754
Guodong Zhu China 17 449 0.9× 203 0.8× 246 1.1× 179 1.9× 63 0.8× 25 761
Meng-Ning Wei China 16 512 1.0× 233 0.9× 149 0.6× 215 2.3× 56 0.7× 23 770
Stephen F. Sarabia United States 15 291 0.6× 176 0.7× 185 0.8× 95 1.0× 118 1.4× 24 736
Chengguang Zhao China 15 285 0.6× 147 0.6× 153 0.7× 106 1.1× 63 0.8× 52 609
Kazuya Kudoh Japan 16 599 1.2× 237 0.9× 93 0.4× 132 1.4× 132 1.6× 48 955
Vijesh Kumar Yadav Taiwan 18 502 1.0× 173 0.7× 147 0.6× 310 3.3× 56 0.7× 41 814
Jianjiang Fu China 5 380 0.8× 166 0.7× 75 0.3× 146 1.6× 61 0.7× 5 591

Countries citing papers authored by You-Take Oh

Since Specialization
Citations

This map shows the geographic impact of You-Take Oh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by You-Take Oh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites You-Take Oh more than expected).

Fields of papers citing papers by You-Take Oh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by You-Take Oh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by You-Take Oh. The network helps show where You-Take Oh may publish in the future.

Co-authorship network of co-authors of You-Take Oh

This figure shows the co-authorship network connecting the top 25 collaborators of You-Take Oh. A scholar is included among the top collaborators of You-Take Oh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with You-Take Oh. You-Take Oh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oh, You-Take, Zhen Chen, Dongsheng Wang, Suresh S. Ramalingam, & Shi‐Yong Sun. (2025). Induction of IL6/STAT3-dependent TRAIL expression that contributes to the therapeutic efficacy of osimertinib in EGFR mutant NSCLC cells. Oncogene. 44(27). 2315–2327. 1 indexed citations
2.
Cai, Shuangyi, Thomas Hu, Frank Schneider, et al.. (2024). Spatially resolved subcellular protein–protein interactomics in drug-perturbed lung-cancer cultures and tissues. Nature Biomedical Engineering. 9(7). 1039–1061. 2 indexed citations
3.
Zhao, Liqun, Lei Zhu, You-Take Oh, et al.. (2021). Rictor, an essential component of mTOR complex 2, undergoes caspase-mediated cleavage during apoptosis induced by multiple stimuli. APOPTOSIS. 26(5-6). 338–347. 4 indexed citations
4.
Oh, You-Take & Shi‐Yong Sun. (2021). Regulation of Cancer Metastasis by TRAIL/Death Receptor Signaling. Biomolecules. 11(4). 499–499. 34 indexed citations
5.
Wang, Jian, You-Take Oh, Zhentian Li, et al.. (2021). RAD52 Adjusts Repair of Single-Strand Breaks via Reducing DNA-Damage-Promoted XRCC1/LIG3α Co-localization. Cell Reports. 34(2). 108625–108625. 10 indexed citations
6.
7.
Oh, You-Take, Guoqing Qian, Jiusheng Deng, & Shi‐Yong Sun. (2018). Monocyte chemotactic protein-induced protein-1 enhances DR5 degradation and negatively regulates DR5 activation-induced apoptosis through its deubiquitinase function. Oncogene. 37(25). 3415–3425. 15 indexed citations
8.
Shi, Puyu, You-Take Oh, Liang Deng, et al.. (2017). Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. Clinical Cancer Research. 23(21). 6567–6579. 113 indexed citations
9.
Oh, You-Take, Ping Yue, & Shi‐Yong Sun. (2017). DR5 suppression induces sphingosine-1-phosphate-dependent TRAF2 polyubiquitination, leading to activation of JNK/AP-1 and promotion of cancer cell invasion. Cell Communication and Signaling. 15(1). 18–18. 10 indexed citations
10.
Oh, You-Take, Liang Deng, Jiusheng Deng, & Shi‐Yong Sun. (2017). The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5. Scientific Reports. 7(1). 8027–8027. 23 indexed citations
11.
Yao, Weilong, You-Take Oh, Jiusheng Deng, et al.. (2016). Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition. Journal of Biological Chemistry. 291(41). 21694–21702. 25 indexed citations
12.
Shi, Puyu, You-Take Oh, Guojing Zhang, et al.. (2016). Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Letters. 380(2). 494–504. 147 indexed citations
13.
Han, Bo, Weilong Yao, You-Take Oh, et al.. (2015). The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5. Oncotarget. 6(19). 17532–17542. 37 indexed citations
14.
Oh, You-Take, Ping Yue, Taofeek K. Owonikoko, Fadlo R. Khuri, & Shi‐Yong Sun. (2014). Abstract 2288: Pharmacological inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs cancer cell response to DR5 activation-induced apoptosis. Cancer Research. 74(19_Supplement). 2288–2288. 1 indexed citations
15.
Oh, You-Take, Ping Yue, Wei Zhou, et al.. (2011). Oncogenic Ras and B-Raf Proteins Positively Regulate Death Receptor 5 Expression through Co-activation of ERK and JNK Signaling. Journal of Biological Chemistry. 287(1). 257–267. 36 indexed citations
16.
Fu, Lei, Yidan Lin, Heath A. Elrod, et al.. (2010). c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL. Molecular Cancer. 9(1). 315–315. 27 indexed citations
17.
Oh, You-Take, Liu X, Ping Yue, et al.. (2010). ERK/Ribosomal S6 Kinase (RSK) Signaling Positively Regulates Death Receptor 5 Expression through Co-activation of CHOP and Elk1. Journal of Biological Chemistry. 285(53). 41310–41319. 60 indexed citations
18.
Oh, You-Take, et al.. (2007). Regulation of cyclin-dependent kinase inhibitor p21WAF1/CIP1 by protein kinase Cδ-mediated phosphorylation. APOPTOSIS. 12(7). 1339–1347. 25 indexed citations
19.
20.
Oh, You-Take, et al.. (2005). PKCδ modulates p21WAF1/CIP1 ability to bind to Cdk2 during TNFα-induced apoptosis. Biochemical and Biophysical Research Communications. 339(4). 1138–1147. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cristina Bugés Breakdown of academic impact, for papers by Virginie Poindessous Breakdown of academic impact, for papers by Swarupa G. Kulkarni Breakdown of academic impact, for papers by Guodong Zhu Breakdown of academic impact, for papers by Meng-Ning Wei Breakdown of academic impact, for papers by Stephen F. Sarabia Breakdown of academic impact, for papers by Chengguang Zhao Breakdown of academic impact, for papers by Kazuya Kudoh Breakdown of academic impact, for papers by Vijesh Kumar Yadav Breakdown of academic impact, for papers by Jianjiang Fu
Rankless by CCL
2026